Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells

Biomedicine and Pharmacotherapy

Volumn 63, Issue 7, 2009, Pages 548-551

  de Souza Thiago, Leandro ^a   Sobral da Costa, Elaine ^a   Lopes, Daiana Vieira ^a   Borojevic, Radovan ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Apoptosis; B cell precursor acute lymphoblastic leukemia; Etodolac; Treatment; Tumor growth

Indexed keywords

ETODOLAC;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOSIS INHIBITION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RACEMIC MIXTURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOSTATIC AGENTS; ETODOLAC; HUMANS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEREOISOMERISM;

EID: 68149160870     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.09.009     Document Type: Article

References (12)

1. Pui C.H., Relling M.V., Campana D., and Evans W.E. Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 62 (2002) 161-179
2. Insel P.A. Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman A.G., Rall T.W., Nies A.S., and Taylor P. (Eds). The pharmacological basis of therapeutics. 8th ed. (1990), Pergamon Press, New York 638-681
3. Kune G.A., Kune S., and Watson L.F. Colorectal cancer risk, chronic illnesses, operations and medications: case-control results from the Melbourne colorectal cancer study. Cancer Res 48 (1988) 4399-4404
4. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Stolley P.D., and Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83 (1991) 355-358
5. Schreinemachers D.M., and Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5 (1994) 138-146
6. Kasum C.M., Blair C.K., Folsom A.R., and Ross J.A. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev 12 (2003) 534-537
7. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231 (1971) 232-235
8. Vogt T., McClelland M., Jung B., Popova S., Bogenrieder T., Becker B., et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 11 (2001) 587-599
9. Zang C., Liu H., Posch M.G., Waechter M., Facklam M., Fenner M.H., et al. Peroxisome proliferator-activated receptor ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res 28 (2004) 387-397
10. Matsuo Y., and Drexler H.G. Establishment and characterization of human B cell precursor-leukemia cell lines. Leuk Res 22 (1998) 567-579
11. Jensen M., Engert A., Goebeler M.A., Weissinger F., Wilhelm M., Osterborg A., et al. A novel pro-apoptotic agent SDX-101 (R-etodolac) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). [abstract]. Blood 102 (2003) 674
12. Vindelov L.L., Christensen I., and Nissen N.A. Detergent-trypsin method for the preparation of nuclei for flow cytometry. Cytometry 3 (1983) 323-327